Sandra De Meyer

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    S De Meyer
    Janssen Infectious Diseases BVBA, B2340 Beerse, Belgium
    J Viral Hepat 20:395-403. 2013
  2. doi request reprint Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Hepatology 56:2106-15. 2012
  3. doi request reprint Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    Sandra M J De Meyer
    Clinical Virology Department, Tibotec BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Acquir Immune Defic Syndr 49:179-82. 2008
  4. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
  5. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
  6. ncbi request reprint Design of HIV-1 protease inhibitors active on multidrug-resistant virus
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1965-73. 2005
  7. doi request reprint Resistance profile of darunavir: combined 24-week results from the POWER trials
    Sandra De Meyer
    Tibotec BVBA, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    AIDS Res Hum Retroviruses 24:379-88. 2008
  8. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
  9. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011
  10. doi request reprint Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010

Collaborators

Detail Information

Publications12

  1. doi request reprint Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    S De Meyer
    Janssen Infectious Diseases BVBA, B2340 Beerse, Belgium
    J Viral Hepat 20:395-403. 2013
    ..Although viral breakthrough with resistance occurred in patients receiving telaprevir monotherapy, half of these patients achieved an SVR upon addition of peginterferon/ribavirin highlighting the importance of combination therapy...
  2. doi request reprint Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial
    Sandra De Meyer
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Hepatology 56:2106-15. 2012
    ..Resistant variants were no longer detectable by study end (median follow-up of 11 months) in 58% of non-SVR patients...
  3. doi request reprint Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    Sandra M J De Meyer
    Clinical Virology Department, Tibotec BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Acquir Immune Defic Syndr 49:179-82. 2008
    ..The objective of this study was to examine the potential of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV-infected, treatment-experienced patient population with no baseline darunavir resistance-associated mutations (RAMs)...
  4. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
    ....
  5. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
    ..60%, respectively). ETR was equally effective in suppressing viral replication in patients infected with HIV-1 subtype B or various HIV-1 non-B subtypes...
  6. ncbi request reprint Design of HIV-1 protease inhibitors active on multidrug-resistant virus
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1965-73. 2005
    ..Crystal structures and molecular modeling were used to rationalize the broad spectrum profile resulting from the extension into the P2' pocket of the HIV-1 protease...
  7. doi request reprint Resistance profile of darunavir: combined 24-week results from the POWER trials
    Sandra De Meyer
    Tibotec BVBA, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    AIDS Res Hum Retroviruses 24:379-88. 2008
    ....
  8. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
    ....
  9. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011
    ..The primary outcome measure was non-inferiority of DRV/r versus LPV/r (HIV type-1 [HIV-1] RNA<50 copies/ml). Here, a detailed 96-week resistance analysis is presented...
  10. doi request reprint Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010
    ....
  11. doi request reprint Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients
    Erkki Lathouwers
    Janssen Infectious Diseases Diagnostics BVBA, Beerse, Belgium
    Antivir Ther 18:289-300. 2013
    ....
  12. ncbi request reprint Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor
    Dominique L N G Surleraux
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1813-22. 2005
    ..Absorption studies in animals indicated that TMC114 has pharmacokinetic properties comparable to currently approved HIV-1 protease inhibitors...